Disc Medicine (NASDAQ:IRON) Chief Executive Officer John Quisel said patient demand for the company’s bitopertin program in erythropoietic protoporphyria, or EPP, remains strong after the company enrolled 183 patients in the APOLLO confirmatory study, above its original target of 150.
Speaking at an H.C. Wainwright event hosted by Senior Analyst Doug Tsao, Quisel said the study’s enrollment pace reflected “tremendous demand and enthusiasm” in both the United States and Europe. He said U.S. enrollment was stopped earlier than expected as the company pursued an accelerated approval pathway, while European sites opened in November and quickly contributed enough patients to reach the 150-patient target by midwinter.